<DOC>
	<DOCNO>NCT02436668</DOCNO>
	<brief_summary>This phase 2/3 evaluate efficacy ibrutinib combination nab-paclitaxel gemcitabine first line treatment patient metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Study Ibrutinib v Placebo , Combination With Nab-paclitaxel Gemcitabine , First Line Treatment Patients With Metastatic Pancreatic Adenocarcinoma ( RESOLVE )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis pancreatic adenocarcinoma . Stage IV disease diagnose within 6 week randomization Adequate hematologic function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥9 g/dL Adequate hepatic renal function define : AST and/or ALT ≤5.0 x upper limit normal ( ULN ) liver metastasis , ≤3 x ULN without liver metastasis Alkaline phosphatase &lt; 3.0 x ULN ≤5.0 x ULN liver bone metastasis present Bilirubin ≤1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin , hemolysis ) Estimated Creatinine Clearance ≥30 mL/min KPS ≥70 . Eastern Cooperative Oncology Group ( ECOG ) 01 Prior therapy : BTK inhibitor , radiotherapy , radiotherapy adjuvant setting , cytotoxic chemotherapy primary disease pancreatic adenocarcinoma . Neuroendocrine ( carcinoid , islet cell ) acinar pancreatic carcinoma Known brain leptomeningeal disease ( CT MRI scan brain required case clinical suspicion central nervous system involvement ) . History stroke intracranial hemorrhage within 6 month prior enrollment . Major surgery within 4 week first dose study drug . Treatment strong cytochrome P450 ( CYP ) 3A inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>